MarijoBilusicMDPhD

PubMed

• 62 citations
  Clinical evaluation of TRICOM vector therapeutic cancer vaccines.
  Ravi A. Madan, Marijo Bilusic, Christopher R. Heery, Jeffrey Schlom, James L. Gulley
  Seminars in Oncology. 2012-06-01
• 44 citations
  Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
  Houssein Abdul Sater, Jennifer L. Marte, Renee N. Donahue, Beatriz Walter-Rodriguez, Christopher R. Heery
  Journal for Immunotherapy of Cancer. 2020-03-01
• 18 citations
  Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response.
  Fatima Karzai, Stephanie M. Walker, Scott Wilkinson, Ravi A. Madan, Joanna H. Shih
  Clinical Cancer Research. 2021-01-15

Journal Articles

• Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial  
  Anari F, O�Neill J, Choi W, Chen DYT, Haseebuddin M, Kutikov A, Dulaimi E, R Alpaugh K, Devarajan K, Greenberg RE, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, L..., European Urologu Oncology, 1/1/2018
•  
  Grenga I, Donahue RN, Gargulak ML, Lepone LM, Roselli M, Bilusic M, Schlom J, Urol Oncol., 1/1/2018
• Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer  
  Meeker CR, Geynisman DM, Egleston BL, Hall MJ, Mechanic KY, Bilusic M, Plimack ER, Martin LP, von Mehren M, Lewis B, Wong YN, J Oncol Pract., 1/1/2016
• A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report From the ClinicalTrialsgov WebSite  
  Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM., Clin Genitourin Cancer., 1/1/2015
• Loss of e-cadherin and retinoblastoma genes in a case of urothelial carcinoma with scrotal metastasis  
  Norberg SM, Oros M, Manucha V, Eun D, Bilusic M., Can J Urol., 1/1/2015
• Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer  
  Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, V..., Eur Urol, 1/1/2015
• Spontaneous tumor lysis syndrome in renal cell carcinoma: a case report  
  Norberg SM, Oros M, Birkenbach M, Bilusic M, Clin Genitourin Cancer., 1/1/2014
• Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma  
  Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tucker JA, Jochems C, Schlom J, Gulley JL, and Madan RA, Cancer Immunol Immunother, 1/1/2014
• Anti-angiogenesis in prostate cancer: knocked down but not out  
  Bilusic M, Wong YN, Asian J Androl., 1/1/2014
• Clinical evaluation of TRICOM vector therapeutic cancer vaccines  
  Madan RA, Bilusic M, Heery CR, Schlom J, Gulley JL., Semin Oncol., 1/1/2012
• Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines  
  Bilusic M, Gulley JL, Cancer Immunol Immunother., 1/1/2012
• Plasmapheresis in the Treatment of Hypertriglyceridemia Induced Pancreatitis: A Community Hospital�s Experience  
  Syed H, Bilusic M, Rhondla C and Tavaria A, J Clin Apher., 1/1/2010
• Congenic BNGH2 � normotensive strain despite increased vasopresor sensitivity and T3 level  
  Bilusic M, Barreto N, Tschannen M, Harris J, Jene S, Jacob HJ, and Kwitek EA, FASEB J, 1/1/2004
• BNGH6 rats for the genetic dissection of hypertension?  
  Bilusic M, Barreto N, Tschannen M, Harris J, Jene S, Jacob HJ, and Kwitek EA, FASEB J, 1/1/2003
• Quantitative trait loci mapping for blood pressure and related phenotypes in a cross between Lyon hypertensive (LH) and Lyon normotensive (LN) rats  
  Bilusic M, Bataillard A, Gao L, Tschannen M, Kwitek EA, Jacob HJ and Sassard J, Hypertension, 1/1/2002
• Digital image analysis of silver-stained nucleolar organizer region--associated proteins in endometrial cytologic samples  
  Mahovlic V, Audy-Jurkovic S, Ovanin-Rakic A, Bilusic M, Veldic M, Babic D, Bozikov J, and Danilovic Z., Analyt Quant Cytol Histol, 1/1/1999
• Nivolumab-associated acute glomerulonephritis: a case report and literature review  
  Jung K, Zeng X, Bilusic M, BMC Nephrol., 1/22/2016
• Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations  
  Gatti-Mays M, Redman JM, Collins JM, Bilusic M, Hum Vaccin Immunother., 1/2./2017
• Immunotherapy of Prostate Cancer: Facts and Hopes  
  Bilusic M, Madan R and Gulley JL., Clin Cancer Res., 1/15/2017
• Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations  
  Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel J..., J Immunother Cancer., 1/4./2018
• Provider and patient burdens of obtaining oral anticancer medications  
  Geynisman DM, Meeker CR, Doyle JL, Handorg EA, Bilusic M, Plimack ER, Wong YN, Am J Manag Care, 1/1./2018
• First-In-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors  
  Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marte JL, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL., Clin Cancer Res, 1/21/2018
• Recurrent bulbar paralysis caused by botulinum toxin type B  
  Bilusic M, Patathil J, Brescia M, McHugh W, Zaboski M and Schanzer B, Clin Infect Dis, 1/15/2008
• Local immunotherapy � a way to convert �cold� tumors to �hot�  
  Bilusic M and Gulley JL., JNCI: Journal of the National Cancer Institute, 1/1./2017
• Mechanisms of Immunotherapy Resistance in mCRPC: Identifying the Enemy on the Visceral Metastatic Battlefield  
  Kim JW, Bilusic M, Plimack ER, Oncology, 1/7./2014
• Join now to see all

Books/Book Chapters

• Cancer Immunotherapy: Paradigms, Practice and Promise. 
  Chapter: Issues in pre-clinical models, clinical trial design and analytical considerations in developing and evaluating novel cancer immunotherapies. 
  Page 455.0 - 474.0Bilusic M, Madan R and Gulley JLEditors: Curiel T.Springer Science + Business Media, New York2013
• Emerging Cancer Therapeutics 
  Chapter: Emerging Treatment Strategies for Metastatic Prostate Cancer: The Next Step Forward 
  Page 597.0 - 612.0Heery CR, Bilusic M and Madan RA.Editors: Gulley J and Abraham J.Demos Medical Publishing, New York2011
• Prostate Cancer: Science and Clinical Practice. 
  Chapter: Castration Resistant Prostate Cancer: Role of Chemotherapy 
  Bilusic MEditors: Mydlo JH and Godec CJ.Academic PressEdition Seco,2015

Abstracts/Posters

• Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatec...
  Gulley JL, Sater HA, Marte J, Donahue RN, Rodriguez BW, Heery CR, Stern M, Thompson D, Cordes LM, Chun G, Karzai F, Bilusic M, Schlom J, Dahut WL, Madan RA, Pinto PA, ASCO Annual Meeting. J Clin Oncol, 1/1/2018
• Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability
  Al Harthy M, Singh H, Karzai F, Arlen P, Theoret M, Marte J, Bilusic M, Couvillon A, Owens H, Hankin A, Cordes L, Rosner I, Strauss J, Figg WD, Schlom J, Dahut W, ..., ESMO Annual Meeting. Annals of Oncology, 1/1/2018
• A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.
  Karzai F, Madan RA, Owens H, Couvillon A, Hankin A, Williams M, Bilusic M, Cordes LM, Trepel JB, Killian K, Meltzer PS, Gulley JL, Lee J, Dahut WL, GU ASCO Annual Meeting. Journal of Clinical Oncology, 1/1/2018
• Immunotherapy for biochemically recurrent prostate cancer.
  Madan RA, Karzai F, Bilusic M, Strauss J, Slovin SF, Harshman LC, Theoret MR, Arlen PM, Rauckhorst M, Couvillon A, Hankin A, Williams M, Kantoff PW, Dahut WL, Schlom J..., GU ASCO Annual Meeting. Journal of Clinical Oncology, 1/1/2018
• Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
  Collins JM, Heery CR, Donahue RN, Palena C, Madan RA, Strauss J, Gatti-Mays ME, Schlom J, Gulley JL, Bilusic M, ASCO Annual Meeting. J Clin Oncol, 1/1/2018
• Combination of a therapeutic cancer vaccine and immune checkpoint inhibitors in prostate cancer.
  Madan RA, Bilusic M, Strauss J, Karzai F, Cordes LM, Arlen PM, Theoret MR, Rauckhorst M, Pritchard C, Sater HA, Couvillon A, Hankin A, Dahut WL, Schlom J, Gulley JL, ASCO Annual Meeting. J Clin Oncol, 1/1/2018
• Del Rivero J, Gramza A, Rausckhorts M, Bilusic M, Karzai F, Strauss J, Cordes L, Dahut WL, Schlom J, Gulley JL, Madan RA, SITC Annual Meeting, 1/1/2017
• Durable complete response with PANVAC and Trastuzumab in metastatic triple positive breast cancer (mTPBC)
  SITC Annual Meeting, 1/1/2017
• A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-res...
  Karzai F, Madan RA, Owens H, Hankin A, Couvillon A, Houston ND, Fakhrejahani F, Bilusic M, Theoret MR, Cordes LM, Trepel JB, Edelman DC, Meltzer PS, Gulley JL, Dahut W..., GU ASCO Annual Meeting, J Clin Oncol, 1/1/2017
• Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
  Fakhrejahani F, Madan RA, Dahut WL, Bilusic M, Karzai F, Cordes LM, Strauss J, Schlom J, Gulley JL, ASCO Annual Meeting, J Clin Oncol, 1/1/2017
• Molecular profiling of cancer outliers
  Jung K, Bilusic M, Pei J, Slifker M, Zhou Y, Flieder DB, Gray P, Plimack ER, ASCO Annual Meeting, J Clin Oncol, 1/1/2017
• Human capital costs of obtaining oral anticancer medications.
  Wong YN, Meeker C, Doyle J, Handorf E, Bilusic M, Plimack ER, Geynisman DM, ASCO Annual Meeting, J Clin Oncol, 1/1/2016
• Small cell carcinoma of the bladder: Comparison of survival in various treatment modalities at Fox Chase Cancer Center (FCCC) from 1995 to 2015.
  Ghatalia P, Jung K, Litwin S and Bilusic M., GU ASCO Annual Meeting. J Clin Oncol, 1/1/2016
• Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.
  Wong YN, Dunbrack R, Brennan T, Andrake MD, Zhou Y, Serebriiskii I, Dulaimi E, Hoffman-Censits JH, Bilusic M, Kutikov A, Viterbo R, Greenberg RE, Chen DYT, Lallas CD, ..., ASCO Annual Meeting. J Clin Oncol, 1/1/2015
• Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer
  Plimack ER, Dunbrack R, Brennan T, Andrake MD, Zhou Y, Serebriiskii I, Dulaimi E, Hoffman-Censits JH, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DYT,..., GU ASCO Annual Meeting. J Clin Oncol, 1/1/2015
• Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase II study.
  Plimack ER, Hoffman-Censits JH, Kutikov A, Greenberg RE, Bilusic M, David Y. T. Chen DYT, Viterbo R, Lallas DL, Lin J, Trabulsi EJ, Geynisman DM, Kelly WK, Smaldone MC..., ASCO Annual Meeting; J Clin Oncol, 1/1/2014
• Relationships among financial distress, emotional symptoms, and overall distress in insured cancer patients.
  Wong YN, Hall MJ, Mechanic K, Geynisman DM, Meeker C, Bilusic M, Plimack ER, von Mehren M, Martin LP, Kreamer KM, Egleston B, ASCO Annual Meeting; J Clin Oncol, 1/1/2014
• A phase 2 randomized clinical trial of samarium-153 EDTMP (Sm-153) +/- PSATRICOM vaccine in metastatic castration resistant prostate cancer (mCRPC) after docetaxel.
  Heery, C., Madan, R., Bilusic, M., Kim, J., Singh, N., Rauckhorst, M., Steinberg, S., Dahut,W., Chen, C., DiPaola, R., Stein, M., Stadler, W., Panicali, D., Hodge, J.,..., ASCO Genitourinary Cancers Symposium; J Clin Oncol, 1/1/2013
• Safety profile of poxviral vaccines: NCI experience.
  Kim JW, Marte JL., Bilusic M., Singh NK., Heery CR., Madan RA., Pazdur M.,McMahon S., Rauckhorst M., Schlom J., and Gulley J.L., ASCO Genitourinary Cancers Symposium; J Clin Oncol, 1/1/2013
• A phase I trial of a yeast based therapeutic cancer vaccine targeting CEA-expressing cancers.
  Bilusic M., Gulley J., Hodge J., Tsang K., Arlen P., Heery C., Rauckhorst M., McMahon S., Intrivici C., Poole D., Jochems C., Schlom J., and Madan R., Gastrointestinal Cancers Symposium; J Clin Oncol., 1/1/2012
• Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer
  Singh NK, Bilusic M, Kim JW, Heery CR, Falk MH, Wood BJ, Pinto PA, Dahut WL, Kaushal A, Couvillon A, Rauckhorst M, Choyke PL, Turkbey IB, Trepel JB, Tsang KY, Schlom J..., ASCO Annual Meeting; J Clin Oncol, 1/1/2012
• First-in-human phase I trial of NHS-IL12 in advanced solid tumors.
  Kim, JW., Heery, CR., Bilusic M., Singh, NK., Madan, RA., Sabzevari H., Schlom J., and Gulley JL, ASCO Annual Meeting; J Clin Oncol, 1/1/2012
• Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer ...
  Heery CR, Madan RA, Bilusic M, Kim JW, Singh NK, Rauckhorst M, Clara Chen C, Dahut WL, Stadler WM, DiPaola RS, Stein MN, Hodge JW, Jeffrey Schlom J and Gulley JL, ASCO Annual Meeting; J Clin Oncol, 1/1/2012
• A phase 2 randomized trial of docetaxel alone or in combination with therapeutic cancer vaccine, CEA-,MUC1-TRICOM
  Heery C., Ibrahim N., Madan R., Mohebtash M., Arlen P., Bilusic M., Kim J., Singh, N., McMahon S., Hodge J., Steinberg S., Schlom J., Hodge J., and Gulley J., San Antonio Breast Cancer Symposium, 1/1/2012
• A phase 2 randomized trial of docetaxel alone or in combination with therapeutic cancer vaccine, CEA-,MUC1-TRICOM.
  Heery C., Ibrahim N., Madan R., Mohebtash M., Arlen P., Bilusic M., Kim J., Singh, N., McMahon S., Hodge J., Steinberg S., Schlom J., Hodge J., and Gulley J., ESMO Annual Meeting, 1/1/2012
• Join now to see all

Lectures

• Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development Course 
  Washington, DC - 1/18/2018
• Medical Management of Prostate Cancer 
  Lafayette Hill, PA - 1/19/2014
• Best of Journals: Prostate Cancer 
  San Francisco, CA - 1/31/2014
• Management of Castrate Resistant Prostate Cancer 
  Nazareth Hospital, Philadelphia, PA - 1/13/2013
• Management of Prostate Cancer 
  Virtua Memorial Hospital, Mt Holly, NJ - 1/15/2013
• Join now to see all